Little Apellis is arming itself for a David and Goliath battle over a blockbuster drug franchise

John Carroll

Editor & Founder

Is a little biotech like Apellis $APLS ready for a David vs. Goliath commercial battle with a well-established pharma player and their ferocious Big Pharma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Little Apellis is arming itself for a David and Goliath battle over a blockbuster drug franchise

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Can Bill Anderson save Bayer?

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

Startup working on oral antibodies shares early ulcerative colitis data

How AI can address ongoing challenges in the life sciences industry

Lit­tle Apel­lis is arm­ing it­self for a David and Go­liath bat­tle over a block­buster drug fran­chise

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Little Apellis is arming itself for a David and Goliath battle over a blockbuster drug franchise